Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327 ...

At the recent SEC meeting for gastroenterology and hepatology held on 27th February 2025, the expert panel reviewed phase 3 ...

Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company pioneering innovative therapies for cancer and viral infections, announces that its chief medical officer, Roger ...

Disitamab vedotin, an antibody-drug conjugate (ADC), targets HER2-expressing cancer cells. It works by binding to HER2, being ...

On March 13, 2025, the US Court of Appeals for the Federal Circuit (Federal Circuit) issued a decision titled In Re: Xencor, Inc. (the ...

Bio (NYSE:IBIO – Get Free Report) was upgraded by equities researchers at StockNews.com to a “sell” rating in a report ...

The WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) continues to closely monitor the genetic and ...

The NYU Global Public Health team was the in-person-event winner of STAT Madness, an annual science competition.

ALZpath, Inc. (ALZpath), a leading developer of diagnostic tools and solutions for Alzheimer's disease and related dementias, announced the addition of Samantha Budd Haeberlein, PhD, to its board ...

Summary: To provide adequate written description for a Jepson claim, the applicant must establish that what is claimed to be well known in the prior art is, in fact, well known in the prior art.

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop ...